[1] MOROZOV VA,LAGAYE S. Hepatitis C virus:Morphogenesis,infection and therapy[J]. World J Hepatol,2018,10(2):186-212.
|
[2] WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[M]. Geneva:Word Health Organization,2018.
|
[3] Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virusrelated hepatocellular carcinoma[J]. J Clin Hepatol,2014,30(5):390-395.(in Chinese)肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志,2014,30(5):390-395.
|
[4] LI B,LI BA. The significance of autoantibodies detection for the diagnosis of primary hepatic carcinoma[J]. Chin J Lab Med,2016,39(2):76-78.(in Chinese)李波,李伯安.自身抗体检测在原发性肝癌诊断中的意义[J].中华检验医学杂志,2016,39(2):76-78.
|
[5] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36(2):277-292.
|
[6] XIE F,YU YC,XUE Z,et al. Screening strategy for primary hepatocellular carcinoma based on different combinations of protein induced by vitamin K absence or antagonist-II,alpha-fetoprotein,and alpha-fetoprotein-L3[J]. J Clin Hepatol,2019,35(9):1975-1979.(in Chinese)谢芳,于乐成,薛珠,等.基于PIVKA-Ⅱ、AFP和AFP-L3不同组合模式的肝细胞癌筛查策略探讨[J].临床肝胆病杂志,2019,35(9):1975-1979.
|
[7] GUAN GW,YAO MJ,QIAN XJ,et al. Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3%in the diagnosis of hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(7):1514-1519.(in Chinese)关贵文,姚明解,钱相君,等.AFP和AFP-L3%联合检测在肝细胞癌诊断中的应用价值[J].临床肝胆病杂志,2019,35(7):1514-1519.
|
[8] CAO YL,SHAN J,GONG ZZ,et al. Interpretation of the TRIPOD statement:A reporting guideline for multivariable prediction model for individual prognosis or diagnosis[J]. Chin J Evid-based Med,2020,20(4):492-496.(in Chinese)曹煜隆,单娇,龚志忠,等.个体预后与诊断预测模型研究报告规范———TRIPOD声明解读[J].中国循证医学杂志,2020,20(4):492-496.
|
[9] National Health and Family Planning Commission of The People’s Republic of China. WS 213-2018 Diagnosis for hepatitis C[J]. J Clin Hepatol,2018,34(8):1619-1621.(in Chinese)中华人民共和国国家卫生和计划生育委员会.WS 213—2018丙型肝炎诊断[J].临床肝胆病杂志,2018,34(8):1619-1621.
|
[10] Bureau of Medical Administration,National Health and Family Planning Comission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
|
[11] OBUCHOWSKI NA,MCCLISH DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices[J]. Stat Med,1997,16(13):1529-1542.
|
[12] ZHOU M,WANG H,ZENG X,et al. Mortality,morbidity,and risk factors in China and its provinces,1990-2017:A systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2019,394(10204):1145-1158.
|
[13] KOZIOL JA,IMAI H,DAI L,et al. Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens[J]. Cancer Immunol Immunother,2018,67(5):835-841.
|
[14] LEE MH,YANG HI,LU SN,et al. Hepatitis C virus genotype1b increases cumulative lifetime risk of hepatocellular carcinoma[J]. Int J Cancer,2014,135(5):1119-1126.
|
[15] BUSATO D,MOSSENTA M,BABOCI L,et al. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment[J]. Expert Rev Clin Pharmacol,2019,12(5):453-470.
|
[16] HWANG HM,HEO CK,LEE HJ,et al. Identification of antiSF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma[J]. J Transl Med,2018,16(1):177.
|
[17] MA H,SUN X,CHEN L,et al. Multiplex immunochips for highaccuracy detection of AFP-L3%based on surface-enhanced raman scattering:Implications for early liver cancer diagnosis[J]. Anal Chem,2017,89(17):8877-8883.
|
[18] YU R,TAN Z,XIANG X,et al. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on realworld clinical data[J]. BMC Cancer,2017,17(1):608.
|